Abstract
• The current randomised, Phase III study (LUME-Lung 1; NCT00805194) was designed to investigate the efficacy and safety of nintedanib 200 mg twice daily (bid) in combination with docetaxel versus placebo and docetaxel for the treatment of patients with advanced or recurrent NSCLC who had previously failed first-line chemotherapy – during this study, patient-reported quality of life (QoL) was recorded at regular intervals using standard QoL questionnaires and so the effect of treatment on prespecified symptoms of interest in patients with NSCLC is also examined RESULTS
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
